Are Commercial EV Chargers Ready to Aid with Household Power Consumption?

The transportation industry now accounts for approximately a quarter of worldwide energy-related direct CO2 emissions, and governments all around the globe have committed to converting their fossil-fuel vehicles to zero-emission ones by adopting electric vehicles. Current electric vehicles (EV) can store approximately 18 to 100 kWh of energy, which may be employed not only for commuting but also for other purposes such as delivering energy to households (V2H) or buildings (V2B), as well as offering ancillary services to the power grid (V2G). In this study, a real test setting including a trending bidirectional charger, an EV, a PV simulator, and household appliances are utilized to evaluate the performance of various V2H components and to learn about the concerns that may arise during V2H operation. The results of the tests on the bidirectional EV charger are presented in this paper. Although the results of the tests on the charger installed in the house are not satisfactory and consistent to the project’s goal, they are released in order to aid future studies in better understanding the true challenges of commercial bidirectional chargers

Impact of CFTR Modulators on Beta-Cell Function in Children and Young Adults with Cystic Fibrosis

Background: To date, no consistent data are available on the possible impact of CFTR modulators on glucose metabolism. The aim of this study was to test the hypothesis that treatment with CFTR modulators is associated with an improvement in the key direct determinants of glucose regulation in children and young adults affected by Cystic Fibrosis (CF). Methods: In this study, 21 CF patients aged 10–25 underwent oral glucose tolerance test (OGTT) before and after 12–18 months of treatment with Lumacaftor/Ivacaftor or Elexacaftor-Ivacaftor-Tezacaftor. β-cell function (i.e., first and second phase of insulin secretion measured as derivative and proportional control, respectively) and insulin clearance were estimated by OGTT mathematical modelling. Insulin sensitivity was estimated by the Oral Glucose Sensitivity Index (OGIS). The dynamic interplay between β-cell function, insulin clearance and insulin sensitivity was analysed by vector plots of glucose-stimulated insulin bioavailability vs. insulin sensitivity. Results: No changes in glucose tolerance occurred after either treatment, whereas a significant improvement in pulmonary function and chronic bacterial infection was observed. Beta cell function and insulin clearance did not change in both treatment groups. Insulin sensitivity worsened in the Lumacaftor/Ivacaftor group. The analysis of vector plots confirmed that glucose regulation was stable in both groups. Conclusions: Treatment of CF patients with CFTR modulators does not significantly ameliorate glucose homeostasis and/or any of its direct determinants

Restoration of CFTR function in patients with cystic fibrosis carrying the F508del-CFTR mutation

<div><p>Restoration of BECN1/Beclin 1-dependent autophagy and depletion of SQSTM1/p62 by genetic manipulation or autophagy-stimulatory proteostasis regulators, such as cystamine, have positive effects on mouse models of human cystic fibrosis (CF). These measures rescue the functional expression of the most frequent pathogenic CFTR mutant, F508del, at the respiratory epithelial surface and reduce lung inflammation in <i>Cftr^F508del</i> homozygous mice. Cysteamine, the reduced form of cystamine, is an FDA-approved drug. Here, we report that oral treatment with cysteamine greatly reduces the mortality rate and improves the phenotype of newborn mice bearing the <i>F508del-CFTR</i> mutation. Cysteamine was also able to increase the plasma membrane expression of the F508del-CFTR protein in nasal epithelial cells from <i>F508del</i> homozygous CF patients, and these effects persisted for 24 h after cysteamine withdrawal. Importantly, this cysteamine effect after washout was further sustained by the sequential administration of epigallocatechin gallate (EGCG), a green tea flavonoid, both <i>in vivo</i>, in mice, and <i>in vitro</i>, in primary epithelial cells from CF patients. In a pilot clinical trial involving 10 <i>F508del-CFTR</i> homozygous CF patients, the combination of cysteamine and EGCG restored BECN1, reduced SQSTM1 levels and improved CFTR function from nasal epithelial cells <i>in vivo</i>, correlating with a decrease of chloride concentrations in sweat, as well as with a reduction of the abundance of <i>TNF/TNF-alpha (tumor necrosis factor)</i> and <i>CXCL8</i> (<i>chemokine [C-X-C motif] ligand 8</i>) transcripts in nasal brushing and TNF and CXCL8 protein levels in the sputum. Altogether, these results suggest that optimal schedules of cysteamine plus EGCG might be used for the treatment of CF caused by the <i>F508del-CFTR</i> mutation.</p></div

Field assessment of guar gum stabilized microscale zerovalent iron particles for in-situ remediation of 1,1,1-trichloroethane

A pilot injection test with guar gum stabilized microscale zerovalent iron (mZVI) particles was performed at test site V (Belgium) where different chlorinated aliphatic hydrocarbons (CAHs) were present as pollutants in the subsurface. One hundred kilograms of 56 μm-diameter mZVI (~ 70 g/L) was suspended in 1.5 m3 of guar gum (~ 7 g/L) solution and injected into the test area. In order to deliver the guar gum stabilized mZVI slurry, one direct push bottom-up injection (Geoprobe) was performed with injections at 5 depths between 10.5 and 8.5 m bgs. The direct push technique was preferred above others (e.g. injection at low flow rate via screened wells) because of the limited hydraulic conductivity of the aquifer, and to the large size of the mZVI particles. A final heterogeneous distribution of the mZVI in the porous medium was observed explicable by preferential flow paths created during the high pressure injection. The maximum observed delivery distance was 2.5 m. A significant decrease in 1,1,1-TCA concentrations was observed in close vicinity of spots where the highest concentration of mZVI was observed. Carbon stable isotope analysis (CSIA) yielded information on the success of the abiotic degradation of 1,1,1-TCA and indicated a heterogeneous spatio-temporal pattern of degradation. Finally, the obtained results show that mZVI slurries stabilized by guar gum can be prepared at pilot scale and directly injected into low permeable aquifers, indicating a significant removal of 1,1,1-TCA

Properties and DEFC tests of Nafion Functionalized titanate nanotubes composite membranes prepared by melt extrusion

Nafion based composites are promising materials to improve the performance of direct ethanol fuel cells. In this work, composite membranes of Nafion and titanate nanotubes functionalized with sulfonic acid groups were prepared by melt extrusion and tested in a direct ethanol fuel cell. Far and mid infrared spectroscopies evidenced the formation of ionic bridges between the sulfonic acid groups of both functionalized nanoparticles and the ionomer. Small angle X ray scattering measurements revealed that the melt extrusion method leads to an uniform distribution of the inorganic phase in the ionomer matrix. Such structural analysis indicated that the improved the proton conduction properties of the composites, even with the addition of a high concentration of functionalized nanoparticles, are an outcome of the synergistic ionic network due to the hydrid organic inorganic proton conducting phases. However, an improvement of the fuel cell performance is observed for 2.5 wt of functionalized titanate nanotubes, which is a result of the lower ethanol crossover and the plasticizing effect of the aliphatic segments of the organic moieties grafted at the surface of the titanate nanoparticle